(24/7 MARKET NEWS) – DBV Technologies (NASDAQ: DBVT) STATED, yesterday evening, that its Phase 3 EPITOPE trial of epicutaneous immunotherapy (EPIT) with Viaskin Peanut in children 1 – 3 years was published in the New England Journal of Medicine, reinforcing the potential of a new food allergy treatment option for this community.
DBV Technologies is trading at $1.76, up $0.11 (+6.67%), on 127K premarket shares traded.
Its 52-week range is $1.08 to $3.43. If it can break through its next key inflection point of $1.80, on stronger volume, its setup is favorable for a potential very large run.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
